Abstract
The effectivity ofSabal serrulata extract in the treatment of symptomatic prostatic hyperplasia was scrutinized in 38 patients. In the course of the 12-month treatment followed up by examinations, the subjective complaints abated in almost 3/4 of the cases. Adverse effects were not encountered. According to uroflowmetry, the average peak flow rate increased from 10.36 ml/s to 14.44 ml/s (p<0.0001), while the average middle stream increased from 6.02 ml/s to 7.45 ml/s (p<0.001). Urinary retention decreased or disappeared in more than 9/10 of the cases. The average amount of the residue decreased by 47 ml (p<0.001). The average volume of the prostate was reduced by 10.6% (p<0.02). On the basis of the favourable results,Sabal serrulata extract is recommended in the treatment of prostatic hyperplasia producing symptoms of mild and moderate severity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bach, D.: Medicamentöse Langzeitbehandlung der BPH. Ergebnisse einer prospectiven 3-Jahresstudie mit dem Sabalextrakt IDS 89.Urologe [B],35, 178 (1995).
Berry, S. J., Coffey, D. S., Walsh, P. C., Ewing, L. L.: The development of human benign prostatic hyperplasia with age.J. Urol., 132, 474 (1984).
Boyle, P., Denis, L.: Status and perspectives in the assessment of drug treatment in BPH. Perspectives in the Drug Treatment of BPH. VIIth International Symposium, Bovenau, Germany, October 21–23, 1994.
Garraway, M.: Epidemiology of, and screening for BPH. Benign Prostatic Hyperplasia: Advanced Course on Therapeutic Modalities and Decision Making. San Lorenz de El Escorial, Spain, October 7–9, 1994.
Glynn, R. J., Champion, E. W., Bouchard, G. R., Silbert, J. E.: The development of benign prostatic hyperplasia among volunteers in the Normative Aging Study.Amer. J. Epidemiol., 121, 78 (1985).
Goldschmidt, A.: Economic aspects in the treatment of BPH. Perspectives in the Drug Treatment of BPH. VIIth International Symposium, Bovenau, Germany, October 21–23, 1994.
Helpap, B., Oehler, U., Weisser, H., Bach, D., Ebeling, L.: Morphology of benign prostatic hyperplasia after treatment with Sabal extract IDS 89 or placebo.J. Urol. Pathol., 3, 175 (1995).
Romics, I., Schmitz, H., Frang, D.: Experience in treating benign prostatic hypertrophy with Sabal serrulata for one year.Int. Urol. Nephrol., 25, 565 (1993).
Rotkin, I. D.: Epidemiology of benign prostatic hypertrophy. Review and speculations. In: Grayhack, J. T. (ed.). Benign Prostatic Hyperplasia. DHEW Publ. US Govt. Printing Office, Washington DC 1976, pp. 105–117.
Szécsi, M., Tóth, I., Julesz, J., Faredin, I., Behnke, B.: Effect of Strogen forte extract on the testicular Δ-5 3β-hydroxysteroid dehydrogenase activity in vitro (Abstract).Eur. J. Endocrinol., 130 (S), 120 (1994).
Tóth, I., Szécsi, M., Julesz, J., Faredin, I., Behnke, B.: Effect of Strogen forte extract on the prostatic 5α-reductase activity in vitro (Abstract).Eur. J. Endocrinol., 130 (S2), 53 (1994).
Tóth, I., Szécsi, M., Julesz, J., Faredin, I., Behnke, B.: In vitro inhibition of testicular Δ5-3β-hydroxysteroid dehydrogenase and prostatic 5α-reductase activities in rats and humans by Strogen forte extract.Int. Urol. Nephrol., 28, 337 (1996).
Watanabe, H.: Natural history of benign prostatic hypertrophy.Ultrasound Med. Biol., 12, 567 (1986).
Weisser, H., Tunn, S., Behnke, B., Krieg, M.: Effect of Sabal serrulata extract IDS 89 and its subfractions on 5α-reductase activity in human benign prostatic hyperplasia.Prostate, 1995 (accepted for publishing).
Report of the Hungarian National Urological Institute, Debrecen, 1995 and 1996 (in Hungarian).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kondás, J., Philipp, V. & Diószeghy, G. Sabal serrulata extract (Strogen forte) in the treatment of symptomatic benign prostatic hyperplasia. International Urology and Nephrology 28, 767–772 (1996). https://doi.org/10.1007/BF02550725
Accepted:
Issue date:
DOI: https://doi.org/10.1007/BF02550725